01.14.08
Merck has signed a licensing agreement for an authorized generic form of its osteoporosis drug, Fosamax, which will be available after the U.S. patent expires in February 2007. The drug's global annual sales are approximately $3 billion.
"We can confirm an authorized generic deal for Fosamax has been signed, although specific details of the deal are proprietary," said Merck spokesman Ron Rogers.
The agreement allows Merck to maintain some of its revenues from the drug after patent protection expires and becomes open to competition from generics.
"We can confirm an authorized generic deal for Fosamax has been signed, although specific details of the deal are proprietary," said Merck spokesman Ron Rogers.
The agreement allows Merck to maintain some of its revenues from the drug after patent protection expires and becomes open to competition from generics.